Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0677 in Primary Fibromyalgia
NCT00116129Phase 2Completed
- Start
- Jul 2005
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibromyalgia (FM) comparing MK-0677 25 mg with Placebo (2 arms). Primary endpoints: Fibromyalgia Impact Questionnaire at 24 weeks and Safety and Tolerability at 24 weeks. Started Jul 2005; status: completed.
02
Drugs
ibutamoren
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT00116129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116129.